a study of a polymeric surfactant technology cleanser in sensitive skin participants

Conditions: Dermatitis, Atopic; Rosacea; Acne Vulgaris; Sensitive Skin

Summary: the purpose of this study is to evaluate the efficacy and tolerance of a gentle facial cleanser in participants with sensitive skin (eczema/atopic dermatitis, rosacea, acne, cosmetic intolerance syndrome).


Eligibility criteria:
inclusion criteria: * male or female 18-70 years of age. participants who are over 65 years of age must be coronavirus disease 2019 (covid-19) vaccinated. the site will review state issued vaccination cards as proof of vaccination * fitzpatrick skin type i-vi, across a range of races and ethnicities with at least 2 participants per each fitzpatrick skin type * participants who possess mild to moderate eczema/atopic dermatitis, mild to moderate rosacea, mild to moderate acne, or mild to moderate cosmetic intolerance syndrome * participants willing to continue normal course of treatment (within the past 30 days) for their skin disease/condition with no changes during the study * participants must provide written informed consent including consent for photograph release including health insurance portability and accountability act (hipaa) disclosure * able to read, write, speak, and understand english * generally in good health based on medical history reported by the participant * intends to complete the study and is willing and able to follow all study instructions exclusion criteria: * has very sensitive skin and/or has known allergies or adverse reactions to common topical skincare products or to ingredients in the investigational product (ip) or have demonstrated a previous hypersensitivity reaction to any of the ingredients in the ip * participants who are pregnant, breast feeding, or planning to become pregnant * participants with clinically significant unstable medical disorders * participants who are unwilling or unable to comply with the requirements of the protocol * participants who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study * participants with any planned surgeries and/or invasive medical procedures during the course of the study * participants who started hormone replacement therapies (hrt) or hormones for birth control less than 3 months prior to study entry or who plan on starting, stopping, or changing doses of hrt or hormones for birth control during the study * presents with a skin or condition that, in the principal investigator (pi) or designee's opinion, may confound the study results or otherwise be inappropriate for study participation (example, pre-existing or dormant facial dermatologic conditions specifically severe acne or acne conglobata, psoriasis, rosacea, rashes, eczema, atopic dermatitis, skin cancer, many and/or severe excoriations, observable suntan, scars, nevi, tattoo, excessive hair, et cetera \[etc\]) * has self-reported type 1 or type 2 diabetes or is taking insulin or another anti-diabetic medication * is taking a medication that would mask an adverse event (ae) or confound the study results, including: a) immunosuppressive or steroidal drugs within 2 months before visit 1; b) non-steroidal anti-inflammatory drugs within 5 days before visit 1; c) antihistamines within 2 weeks before visit 1 * has a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study * is simultaneously participating in any other product-use study or has participated in another clinical study on the face in the past 4 weeks * participants currently receiving any anticancer, immunosuppressive treatments/medications (example, azathioprine, belimumab, cyclophosphamide, enbrel, imuran, humira, mycophenolate mofetil, methotrexate, prednisone, remicade, stelara.), or radiation as determined by study documentation * participants with a history of immunosuppression/immune deficiency disorders (including \[human immunodeficiency virus {hiv} infection or acquired immunodeficiency syndrome {aids}) * is participating or receiving any professional or aesthetic facial spa procedures during the study * is an employee/contractor or immediate family member of the pi, study site, or sponsor * has a history of a confirmed covid-19 infection within 30 days prior to visit 1 * has had contact with a covid-19-infected person within 14 days prior to visit 1 * individual or a member of the individual's household has traveled internationally within 14 days prior to visit 1 * has experienced any of the following self-reported symptoms of covid-19 within 2 weeks prior to visit 1: a) unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomachaches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, fever, or chest pain/tightness; b) temperature greater than or equal to (\>=) 37.5 degree celsius (°c) / 99.5 degree fahrenheit (°f), measured; c) use of fever reducers within 2 days prior to each on-site visit